These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer. Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553 [No Abstract] [Full Text] [Related]
3. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088 [TBL] [Abstract][Full Text] [Related]
4. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds. Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568 [TBL] [Abstract][Full Text] [Related]
5. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models. Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901 [TBL] [Abstract][Full Text] [Related]
6. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151 [TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556 [TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641 [TBL] [Abstract][Full Text] [Related]
9. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors. Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023 [TBL] [Abstract][Full Text] [Related]
14. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586 [TBL] [Abstract][Full Text] [Related]
15. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models. Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058 [TBL] [Abstract][Full Text] [Related]
16. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336 [TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791 [TBL] [Abstract][Full Text] [Related]
18. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Sheng Q; Liu X; Fleming E; Yuan K; Piao H; Chen J; Moustafa Z; Thomas RK; Greulich H; Schinzel A; Zaghlul S; Batt D; Ettenberg S; Meyerson M; Schoeberl B; Kung AL; Hahn WC; Drapkin R; Livingston DM; Liu JF Cancer Cell; 2010 Mar; 17(3):298-310. PubMed ID: 20227043 [TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627 [TBL] [Abstract][Full Text] [Related]
20. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. Shin DH; Jo JY; Han JY Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]